GlassScriptPhysician profile
Oluchi Chilaka
NPI 1336651520
$22,341.15
in general payments reported to CMS, 2019-2025
21 companies · $6,412 in 2025
The $6,412 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,440 · 2022: $3,127 · 2023: $4,260 · 2024: $6,102 · 2025: $6,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,393.50 |
| Education | $380.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,574.01 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $4,098.46 | 2021-2025 | |
| Alkermes, INC. | $3,439.26 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $2,724.48 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,827.96 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,825.49 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $725.67 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $699.52 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $520.95 | 2024-2025 | Qelbree |
| Lundbeck LLC | $380.49 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $353.79 | 2023-2025 | Auvelity |
| Corium, LLC | $330.05 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $254.26 | 2023-2025 | Invega Sustenna, Spravato |
| Sunovion Pharmaceuticals INC. | $162.41 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $111.40 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.24 | 2022-2023 | Trintellix |
| Bausch Health US, LLC | $77.33 | 2024 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $56.46 | 2024-2025 | Loreev Xr |
| Validus Pharmaceuticals LLC | $33.27 | 2025 | Equetro, Raldesy |
| Indivior INC. | $33.17 | 2023-2024 | Perseris, Sublocade |
| Luye Pharma (USA) LTD. | $32.48 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oluchi Chilaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.